Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Spinal metastasis and cord compression

Musculoskeletal medicine and orthopaedics · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Escalate

Metastatic spinal cord or cauda-equina compression is an oncological emergency. For cancer with new limb weakness, gait disturbance, sensory loss or bladder or bowel dysfunction, contact the named MSCC coordinator immediately and immobilise when instability is suspected. Administer oral dexamethasone 16 mg promptly, using the equivalent parenteral dose if the oral route is unsuitable; continue 16 mg daily while definitive treatment is awaited and complete whole-spine MRI urgently, no later than 24 hours. Do not route the patient through routine back-pain care.

Synopsis

Recognise metastatic spinal instability and neurological compression early, activate the NICE emergency pathway and coordinate safe positioning, whole-spine MRI, corticosteroid and definitive surgery or radiotherapy.

  • Cancer plus new weakness, gait change, sensory loss or sphincter disturbance is MSCC until proved otherwise and requires immediate coordinator contact.
  • Gold-standard imaging is whole-spine MRI, completed urgently and no later than 24 hours whenever metastatic cord compression is suspected.
  • Do not use plain spinal radiography to exclude MSCC; CT is used for bony stability or when MRI is contraindicated, with myelography only in specialist settings.
  • For neurological symptoms or signs, give dexamethasone 16 mg promptly, continue 16 mg daily while definitive surgery or radiotherapy is awaited and monitor glucose and gastrointestinal risk.
  • Begin immobilisation without delay when neurological features accompany suspected instability; individualise supine positioning if pain, breathing or pressure risk makes it harmful.
  • Use the Spinal Instability Neoplastic Score as decision support alongside clinical and imaging judgement, not as a substitute for spinal surgical review.
  • Definitive first-line local treatment is urgent decompression with stabilisation for suitable patients or urgent radiotherapy when surgery is unsuitable.
  • Start bladder, bowel, pressure-area, thrombosis and rehabilitation care at presentation because preserving survival without function is an avoidable failure.

Key red flags

New weakness, falls, gait change, sensory level or limb numbness in a person with current or previous cancer is possible cord compression.

Urinary retention, overflow, loss of bladder sensation, faecal incontinence or saddle sensory change suggests cord or cauda-equina dysfunction.

Severe progressive night spinal pain, band-like radicular pain, pain on coughing or movement and focal tenderness can precede neurological loss.

Mechanical pain that prevents sitting, standing or turning suggests vertebral instability and requires movement protection while stability is assessed.

A normal spinal radiograph cannot exclude epidural tumour, marrow replacement or cord compression and must not delay emergency MRI.

When lymphoma or myeloma is suspected without neurological signs, discuss corticosteroid timing with haematology because treatment can reduce diagnostic tissue yield.

Investigation priorities

01
Gold-standard whole-spine MRI within 24 hoursFirst step

Identify all levels of epidural compression, cord signal, marrow disease, fracture and soft-tissue extent.

Management branches

Immediate neurologicalActivate MSCC rescue

Cancer and new weakness, gait, sensory or bladder or bowel dysfunction indicate possible compression.

  1. Contact the MSCC coordinator and spinal or oncology service immediately and document the time and neurological baseline.
  2. Give dexamethasone 16 mg promptly, then 16 mg daily while definitive treatment is awaited, with glucose and gastric protection.
  3. Immobilise if instability is suspected, transfer with alignment protection and individualise position for breathing and pressure safety.
  4. Obtain whole-spine MRI as soon as possible and within 24 hours, escalating any deterioration during the wait.

Key medicines

Dexamethasone for neurological MSCCGive 16 mg orally as soon as possible, or an equivalent parenteral dose when oral administration is unsuitable, then continue 16 mg daily while surgery or radiotherapy is awaited.Monitor capillary glucose, infection, delirium, myopathy and gastrointestinal risk; provide proton-pump protection and taper after treatment begins, stopping safely if MSCC is excluded.
Omeprazole during high-dose corticosteroid treatmentUse omeprazole 20 mg orally once daily while high-dose dexamethasone is required, adjusting choice and route for interactions, swallowing and local formulary guidance.Review magnesium and infection risk with prolonged use and interactions where relevant; it does not remove the need to minimise steroid duration.
Open full textbook →Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG234 MSCC RecommendationsEmergency recognition, positioning, MRI, dexamethasone, surgery, radiotherapy and rehabilitation.
  • NICE NG234 Rationale and ImpactEvidence context for imaging, corticosteroid and definitive treatment choices.
  • NICE BNF DexamethasoneCorticosteroid contraindications, interactions and adverse-effect monitoring.
  • NICE NG89 VTE PreventionThrombosis and bleeding assessment during cancer-related immobility.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom